SCHEMBL944688

SCHEMBL944688

O=C(O)c1ccc(NC(=O)c2ccc(Cl)nc2)c(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.57
MDM4 O15151 1/20 0.56
TP53 P04637 1/20 0.56
MDM2 Q00987 1/20 0.56
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
P4HTM Q9NXG6 1/20 0.51
KDR P35968 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
POLB P06746 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KCNQ3 O43525 3/20 0.47
KCNQ2 O43526 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19405814 0.88 MDM4 (0.54) MDM4TP53MDM2KMT2AMEN1
SCHEMBL21462534 0.87 MDM4 (0.57) MDM4TP53MDM2KMT2AMEN1
SCHEMBL19405896 0.85 MDM4 (0.52) MDM4TP53MDM2KMT2AMEN1
SCHEMBL944877 0.83 MEN1 (0.54) TP53KMT2AMEN1RAB9AP4HTM
SCHEMBL4737278 0.82 RAB9A (0.57) NAPRTMDM4TP53MDM2KMT2A
SCHEMBL3199765 0.82 P4HTM (0.56) MDM4TP53MDM2KMT2AMEN1
SCHEMBL21462469 0.81 TP53 (0.72) MDM4TP53MDM2KMT2AMEN1
SCHEMBL29692929 0.80 KDM5A (0.59) KMT2AMEN1RAB9AL3MBTL1MAPT
SCHEMBL28931514 0.80 MEN1 (0.60) TP53KMT2AMEN1RAB9AL3MBTL1
SCHEMBL16689759 0.80 MEN1 (0.60) TP53KMT2AMEN1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338459-B2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, INC. (US) 2012-12-25 US disclosed
US-8338459-B2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, INC. (US) 2012-12-25 US disclosed
US-8338459-B2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, INC. (US) 2012-12-25 US disclosed
EP-2314584-A1 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Foldrx Pharmaceuticals, Inc. (US) 2011-04-27 EP disclosed
EP-2314584-A1 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Foldrx Pharmaceuticals, Inc. (US) 2011-04-27 EP disclosed
US-20110092545-A1 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding FoldRx Pharmaceuticals, Inc., a Massachusetts corporation 2011-04-21 US disclosed
US-20110092545-A1 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding FoldRx Pharmaceuticals, Inc., a Massachusetts corporation 2011-04-21 US disclosed
US-20110092545-A1 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding FoldRx Pharmaceuticals, Inc., a Massachusetts corporation 2011-04-21 US disclosed
US-7868033-B2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, INC. (US) 2011-01-11 US disclosed
US-7868033-B2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, INC. (US) 2011-01-11 US disclosed
US-7868033-B2 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, INC. (US) 2011-01-11 US disclosed
EP-1768968-A1 2-((HETERO) ARYL)-BENZOXAZOLE COMPOUNDS AND DERIVATIVES, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING Foldrx Pharmaceuticals, Inc. (US) 2007-04-04 EP disclosed
US-20050282780-A1 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding FOLDRX PHARMACEUTICALS, LLC 2005-12-22 US disclosed
WO-2005113523-A1 2-((HETERO) ARYL)-BENZOXAZOLE COMPOUNDS AND DERIVATIVES, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING FOLDRX PHARMACEUTICALS, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092545-A1 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding TTR, ALB, TTPA NAPRT 3726/4885MDM4 2518/4885TP53 226/4885
US-20050282780-A1 Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding TTR, ALB, TTPA NAPRT 3726/4885MDM4 2518/4885TP53 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.